Navigation Links
KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation
Date:4/8/2008

Settlement in Principle Would Bring To Close Derivative Lawsuit Filed in

October 2006

ST. LOUIS, April 8, 2008 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that it has reached a comprehensive settlement agreement in principle with the plaintiffs in a derivative lawsuit relating to the Company's historic stock option granting practices, subject to limited confirmatory discovery and court approval. Fees and costs awarded by the Court are expected to be covered by insurance.

Upon final Court approval of the settlement agreement, all private securities litigation pending against the Company regarding the stock option matter will be resolved.

"Upon its finalization, the settlement of this litigation will be another step, along with the recent filing of the Company's Form 10-Q's and Form 10-K for Fiscal 2007, towards putting the entire option issue behind us," stated Marc S. Hermelin, Chairman of the Board.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology- distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate website at http://www.kvpharmaceutical.com.

Safe Harbor

The information in this release may contain vari
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
2. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
3. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
4. China Shenghuo Pharmaceutical Holdings, Inc. to Present at Brean Murray Carret & Co. Mainland China Investor Tour
5. Breckenridge Pharmaceutical Enters Agreement With Helm AG (Hamburg, Germany) to Develop Additional ANDA Project
6. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
7. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
8. Benda Pharmaceutical Reports Fourth Quarter and Full Year 2007 Financial Results
9. Pharmaceutical Strategic Initiatives Adds Anne Sexton, MD, MS to Management Team
10. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
11. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...HASSEE, Fla. -- A Florida State University College...s discovered an important new layer of regulation ...greater understanding of the way cancer begins. ,...ces at the College of Medicine, said the findings ...r and could lead to the design of new drugs that k...
(Date:11/21/2008)... Colo., Nov. 21 Heska Co...ll present at the New York Society of,Security An...onference on,December 2, 2008 at 1177 Avenue of t...ntation is scheduled to begin at 9:35 a.m. Eastern...able via live webcast and for two weeks,following...
(Date:11/21/2008)...rchers remain cautious about future antibiotic res..., Nov. 21 (HealthDay News) -- People with moderate...COPD) may be able to reduce the frequency of exace...ntibiotic, a new report says. , The study, pub...rican Journal of Respiratory and Critical Care Med...
(Date:11/21/2008)...Nov. 21 The University... beginning of a collaborative effort to eradicate ...r Breast Cancer Awareness and Research of the Amer...Lady of the United States, and Vivian Fernandez de...ining M. D. Anderson in the initiative are the U.S...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3
...transvaginal ultrasound scans can do away with inv... tests, used for determining// a woman’s success r...Kwee from Vrije Universiteit Medical Center in Ams...e ovaries of women subjects in an IVF program. ...
...re consuming very little of vegetables and fruits ...d other ailments//. This was disclosed by Heidi Bl... Blanck found that 32.6% of the respondents had fr...umed vegetables thrice or more than thrice per day...
...health caused by an unintentional injury or new ch...likely to have difficulty// obtaining recommended ...declines in short-term health, according to a stud...nstitute, Washington, D.C., presented the results ...
...rary of Science) suggests that computers could gue...lating// the wishes of a terminally sick patient. ...tumbled upon this finding while he was analyzing t...ne on the course of action involving a critically ...
Other Medicine News:Health News:Cheaper and Quicker Alternative to Ovarian Reserve Tests 2Health News:Uninsured Often Receive Less Medical Care 2
(Date:11/19/2008)...on Payment from Roche- , , MONTVALE, N.J., ...ticals Corp. (Nasdaq: MEMY ) today announced tha...e 2 trial of R3487/MEM 3454, its lead alpha-7 nico...sociated with schizophrenia (CIAS). The Company h...riggering a $5.0 million payment from its partner ...
(Date:11/18/2008)...v. 18 Forty-two leading...vember national forum to consider cutting-edge inn...nd national economy from outbreaks of dangerous zo..., , Among those innovations: , , , ...tchen table that detects highly contagious and dan...
(Date:11/13/2008)...ests Nutritional Supplements Prior to Surgery, AR...ire/ -- Identifying,malnutrition before surgery in...ing will significantly decrease surgical complicat...ty and boost patient energy levels,according to a...tructive,Surgery(R), the official medical journal ...
(Date:11/12/2008)...o and LOD, Israel, November 12 Sur...r, NY indicated that,patient-specific CTA data can...Mentor(TM), Simbionix US) with high face validity....n improved the operative flow,increased patient s...overall operative and fluoroscopy time and the amo...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Night Hospitalist Company LLC Launches First Nighttime Hospitalist Telemedicine Solution 22612 1Night Hospitalist Company LLC Launches First Nighttime Hospitalist Telemedicine Solution 22612 2URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 1URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 2URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 3URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 4URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 5New Generation Biofuels Set to Join Russell Microcap Index 6178 1New Generation Biofuels Set to Join Russell Microcap Index 6178 2New Generation Biofuels Set to Join Russell Microcap Index 6178 3Pressure BioSciences Inc Announces 24850 000 NIH SBIR Phase II Award for the Development of a New PCT dependent System for Improved Biomarker Disco 2509 1Pressure BioSciences Inc Announces 24850 000 NIH SBIR Phase II Award for the Development of a New PCT dependent System for Improved Biomarker Disco 2509 2Pressure BioSciences Inc Announces 24850 000 NIH SBIR Phase II Award for the Development of a New PCT dependent System for Improved Biomarker Disco 2509 3Pressure BioSciences Inc Announces 24850 000 NIH SBIR Phase II Award for the Development of a New PCT dependent System for Improved Biomarker Disco 2509 4
...sitive Phase IIa Clinical,Trial Results, First cli... Key,Product in AM-Pharma,s Pipeline , BUNNIK, The...pharmaceutical company developing novel therapeuti...today announced the positive,clinical results of i...atients with ulcerative colitis, a chronic and rel...
...nc. (NASDAQ:INSM), a ,biopharmaceutical company fo... the treatment of metabolic diseases with unmet,m...t at this,week,s C.E. Unterberg, Towbin (CEUT) Eme...City. , The conference, to be held at the Manda...m Tuesday, July 10th through Thursday,July 12th. ...
Other Medicine Technology:AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
...erior Chamber Lenses: The Bausch & Lomb PMMA Poste... used for primary implantation for the visual corr...lder where a cataractous lens has been removed by ... intended to be placed in the ciliary sulcus or ca...
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia.
Multipiece PMMA IOL - Sulcus Fixation.
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia.
Medicine Products: